Preclinical models suggest that specific blockade of TNFR2 may significantly reduce inflammation and ameliorate signs of psoriatic diseases, while maintaining normal immune response in the host, including the ability to combat infection and cancer. In this article, M. Elaine Husni, MD, MPH, highlights her latest research and discusses her plans to use her new R01 grant to continue her translational work.
Our laboratory tests whether aberrant levels of plasma and tissue L-arginine metabolites serve as an early, non-invasive predictor of CV disease in psoriatic patients.
The Husni research lab combines clinical savvy with biochemical and molecular biology expertise to home in on the molecular basis of immune-mediated diseases. An early focus: selective TNF-α receptor inhibition.